| [1] |
Chen W, Zheng R, Zeng H, et al. Annual report on status of cancer in China,2011[J]. Chin J Cancer Res,2015;27(1):2-12.
|
| [2] |
Pennati M, Millo E, Gandellini P, et al. RNA interferencemediated validation of survivin and Apollon/BRUCE as new therapeutic targets for cancer therapy [J]. Curr Top Med Chem,2012,12(2):69-78.
|
| [3] |
宫惠琳, 张锁平, 张冠军, 等. Survivin、MMP-2 在乳腺癌中的表达及其相关性研究[J]. 重庆医科大学学报, 2012,37(2):106-109.
|
| [4] |
曹丹霞, 何建蓉, 沈坤炜, 等. 激素受体和HER-2 及Ki-67预测乳腺癌新辅助化疗疗效价值的分析[J]. 中华肿瘤防治杂志,2012,19(13):1000-1003.
|
| [5] |
Cotter TG. Apoptosis and cancer:the genesis of a research field[J]. Nat Rev Cancer,2009,9(7):501-507.
|
| [6] |
Deveraux QL,Reed JC. IAP family proteins--suppressors of apoptosis[J]. Genes Dev,1999,13(3):239-252.
|
| [7] |
Hauser HP, Bardroff M, Pyrowolakis G, et al. A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors[J]. J Cell Biol,1998,141(6):1415-1422.
|
| [8] |
Qiu XB, Goldberg AL. The membrane-associated inhibitor of apoptosis protein, BRUCE/Apollon, antagonizes both the precursor and mature forms of Smac and caspase-9[J]. J Biol Chem,2005,280(1):174-182.
|
| [9] |
Hao Y, Sekine K, Kawabata A, et al. Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function[J]. Nat Cell Biol,2004,6(9):849-860.
|
| [10] |
Ismail EA, Mahmoud HM, Tawfik LM, et al. BIRC6/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis[J]. Eur J Haematol,2012,88(2):118-127.
|
| [11] |
Low CG, Luk IS, Lin D, et al. BIRC6 protein, an inhibitor of apoptosis: role in survival of human prostate cancer cells[J].PLoS One,2013,8(2):e55837.
|
| [12] |
Wang L, Chen YJ, Hou J, et al. Expression and clinical significance of BIRC6 in human epithelial ovarian cancer[J].Tumour Biol,2014,35(5):4891-4896.
|
| [13] |
罗力亚, 刘风玲. HER2 /neu 在肿瘤中研究进展及抗HER2/neu 治疗[J]. 现代肿瘤医学, 2011,19 (12):2573-2576.
|
| [14] |
Barnes DM. c-erbB-2 amplification in mammary carcinoma[J]. J Cell Biochem Suppl,1993,17G:132-138.
|
| [15] |
董营,康丽花,关萌,等.乳腺癌患者术后辅助治疗的临床效果及其影响因素分析[J]. 吉林大学学报(医学版), 2015,41(3):636-642.
|
| [16] |
Song J, Su H, Zhou YY, et al. Prognostic value of survivin expression in breast cancer patients: a meta-analysis [J].Tumour Biol,2013,34(4):2053-2062.
|
| [17] |
陈建发,岳志强,傅明,等. 新辅助化疗前apollon 在乳腺癌组织中的表达及意义[J]. 南方医科大学学报, 2015,35(8):1201-1205.
|
| [18] |
李庆霞, 颜聪亚, 闫晓路, 等. 乳腺浸润性导管癌组织FGFR1 和Survivin 表达临床意义分析[J]. 中华肿瘤防治杂志,2013,20(17):1315-1318.
|
| [19] |
Zhang H, Jin F. HER-2 expression correlates with survivin in primary invasive ductal breast cancers[J]. Asian Pac J Cancer Prev,2010,11(5):1201-1204.
|
| [20] |
Ryan BM, Konecny GE, Kahlert S, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1[J]. Ann Oncol,2006,17(4):597-604.
|
| [21] |
Fuzhong T, Nan L, Jiajia G, et al. Clinical significance of the relationship between expression of survivin and effects of neoadjuvant chemotherapy in locally advanced breast cancer[J]. Gan To Kagaku Ryoho,2008,35(8):1319-1323.
|
| [22] |
Zhang M, Zhang X,Zhao S,et al. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer(TNBC) patients[J]. Target Oncol,2014,9(4):349-357.
|
| [23] |
张真,张小涛,于兰,等. 乳腺癌CD44v6 和Survivin 的表达与临床预后的相关性研究[J]. 中国肿瘤临床, 2011,38(14):835-838.
|
| [24] |
桑占发,王兴,齐玉新,等. survivin 在乳腺癌中的表达及其与Ki-67 和c-erbB-2 表达的关系[J]. 肿瘤防治研究,2010,37(7):773-776.
|